Kodiak Sciences Inc (FRA:K27)
€ 3.546 0.072 (2.07%) Market Cap: 211.94 Mil Enterprise Value: 80.00 Mil PE Ratio: 0 PB Ratio: 0.96 GF Score: 37/100

Kodiak Sciences Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 04:30PM GMT
Release Date Price: €111 (+15.03%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Hello, everyone. My name is Gena Wang. I'm smid-cap biotech analyst at Barclays. Welcome to our second virtual Global Healthcare Conference. First, I wish everyone to stay healthy, and I would like to thank all the participants, investors, companies and especially our event team, our corporate access team who made this virtual healthcare conference possible.

With that, I would like to introduce our next presenter, Victor Perlroth from -- Chief Executive Officer from Kodiak. Victor, I hand over to you.

Victor Perlroth
Kodiak Sciences Inc. - Chairman, MD, CEO & President

Thank you so much, Gena, and thanks to the Barclays team for having us at the conference.

We'll move in to our presentation. Thank you very much. I'm the Chief Executive Officer of Kodiak Sciences. We're an ophthalmology-focused biotech, in particular, focused on new treatments for diseases in retina.

Please note, there'll be some forward-looking statements made in the discussion.

So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot